search
Back to results

Quantitative Assessment of Hypertrophic Obstructive Cardiomyopathy With Intraoperative Three-dimensional Transesophageal Echocardiography Under Provocative Dobutamine Stress Test

Primary Purpose

Hypertrophic Obstructive Cardiomyopathy

Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Pre and post-CPB Drug: Dobutamine Hydrochloride
Post-CPB Drug: Dobutamine Hydrochloride
Sponsored by
University Health Network, Toronto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Hypertrophic Obstructive Cardiomyopathy focused on measuring Transesophageal Echocardiography, Dobutamine Stress test

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. HOCM refractory to medical treatment with symptoms like syncope, angina or NYHA functional classes III and IV, with a resting gradient or provocable gradient equal or greater than 50 mmHg, requiring surgical intervention.
  2. Absence of other cardiac or systemic diseases capable of producing hypertrophy.
  3. Sinus rhythm.

Exclusion Criteria:

  1. Patient refusal.
  2. Patient unable to give consent.
  3. TEE contraindication.
  4. Different rhythm than sinus.
  5. Other systemic diseases capable of producing hypertrophy.
  6. Severe Aortic or coronary artery pathology.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Preoperative Transesophageal Echocardiogram (TEE) PG under anesthesia <50mmHg (Group A)

    Preoperative PG under anesthesia ≥ 50mmHg (Group B)

    Arm Description

    Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG under DBT stress test at 5, 10, 15 and 20 mcg/kg/min or until a PG ≥ 50mmHg is achieved, will be recorded. Post-CPB (post-myectomy) echocardiographic parameters: PG at DBT peak dose (DBT-pd) will be recorded. If LVOT PG post myectomy are >16 mmHg, the surgeon will be advised, for surgical management considerations.

    Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG without DBT stress test will be recorded. Post-CPB (post-myectomy) echocardiographic parameters: PG at 5, 10, 15, 20 mcg/kg/min DBT stress test or until the postoperative provocable PG is >16 mmHg will be recorded.

    Outcomes

    Primary Outcome Measures

    Analyze if TEE immediate post-myectomy LVOT gradients, may be reproduced with provocation dobutamine test in HOCM patients, when compared to TTE LVOT gradients performed within 6 months post-myectomy, to prove septal myectomy efficacy.
    The preoperative gradients obtained by TTE, with and without stress test, within 6 months pre-myectomy, will be compared with the intraoperative TEE pre-myectomy gradients at baseline (before and after DBT stress test). The post-myectomy TEE gradients (before and after DBT stress test), will be compared with the follow up TTE gradients with and without stress test, performed within 6 months post-myectomy, to assess short term outcomes.

    Secondary Outcome Measures

    Full Information

    First Posted
    August 11, 2021
    Last Updated
    November 4, 2022
    Sponsor
    University Health Network, Toronto
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05025644
    Brief Title
    Quantitative Assessment of Hypertrophic Obstructive Cardiomyopathy With Intraoperative Three-dimensional Transesophageal Echocardiography Under Provocative Dobutamine Stress Test
    Official Title
    Quantitative Assessment of Hypertrophic Obstructive Cardiomyopathy With Intraoperative Three-dimensional Transesophageal Echocardiography Under Provocative Dobutamine Stress Test
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    March 2023 (Anticipated)
    Primary Completion Date
    August 2024 (Anticipated)
    Study Completion Date
    November 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University Health Network, Toronto

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    The objectives of this study are to determine if the left ventricle outflow tract (LVOT) gradients may be reproduced with dobutamine (DBT) provocation test in obstructive HCM patients under general anesthesia and to analyze the change in anatomic LVOT area and pressure gradients (PG) before and after septal myectomy. If the DBT stress test can reproduce preoperative gradients in HCM patients during septal myectomy surgery, surgeons will have the opportunity to assess the quality of the surgical procedure depending on the obtained gradients with DBT stress test after surgery when gradients can't be reproduced during general anesthesia after myectomy, and decide if further myectomy is required, saving a re-operation on the patient in the future.
    Detailed Description
    Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy. Echocardiography is the noninvasive method of choice for the evaluation of morphologic and functional abnormalities in HCM. It is of paramount importance to distinguish between obstructive or non-obstructive HCM, based on the presence or absence of left ventricle outflow tract (LVOT) gradient using continuous wave Doppler (CWD), under resting and/or provocable conditions. HCM can then be divided into three different subgroups. When the gradient at rest is ≥ 30 mmHg the HCM is considered obstructive (HOCM); when the gradient is <30 mmHg at rest but ≥ 30 mmHg with provocation, the HCM is considered latent obstructive, and finally, non-obstructive occurs when the gradient is < 30mmHg at rest or with provocation. The gold standard technique to treat symptomatic HOCM is the surgical transaortic septal myectomy, when the resting gradient or the provocable gradient is ≥50 mmHg. Hemodynamic conditions may change and lead to worsening or improvement in LVOT obstruction during general anesthesia. LVOT gradients during surgery should be measured under reproducible conditions possibly mimicking preoperative hemodynamics. Dobutamine is a well-known inotropic agent, capable to induce sub-aortic gradients in HOCM. The development of a dynamic LVOT gradient during this test is a pharmacological phenomenon with no clinical significance, not been associated with increased frequency of chest pain, shortness of breath or ischemic wall motion abnormalities, because obstruction resolves after termination of dobutamine (DBT) infusion.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertrophic Obstructive Cardiomyopathy
    Keywords
    Transesophageal Echocardiography, Dobutamine Stress test

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Model Description
    This is a monocentric Phase IV prospective study that will be conducted on patients undergoing surgical myectomy treatment for HOCM, at Toronto General Hospital, to assess if LVOT gradients may be reproduced with dobutamine provocation test in HOCM patients under general anesthesia. The participants in the study will require a standard 2D echocardiography within 6 months pre and post-surgery. Intraoperatively, the patients will be divided into two groups, one with preoperative PG under anesthesia <50mmHg (Group A), and one with preoperative PG under anesthesia ≥ 50mmHg (Group B).
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    60 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Preoperative Transesophageal Echocardiogram (TEE) PG under anesthesia <50mmHg (Group A)
    Arm Type
    Experimental
    Arm Description
    Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG under DBT stress test at 5, 10, 15 and 20 mcg/kg/min or until a PG ≥ 50mmHg is achieved, will be recorded. Post-CPB (post-myectomy) echocardiographic parameters: PG at DBT peak dose (DBT-pd) will be recorded. If LVOT PG post myectomy are >16 mmHg, the surgeon will be advised, for surgical management considerations.
    Arm Title
    Preoperative PG under anesthesia ≥ 50mmHg (Group B)
    Arm Type
    Experimental
    Arm Description
    Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG without DBT stress test will be recorded. Post-CPB (post-myectomy) echocardiographic parameters: PG at 5, 10, 15, 20 mcg/kg/min DBT stress test or until the postoperative provocable PG is >16 mmHg will be recorded.
    Intervention Type
    Drug
    Intervention Name(s)
    Pre and post-CPB Drug: Dobutamine Hydrochloride
    Other Intervention Name(s)
    Transthoracic or 2D Echocardiogram, Transesophageal Echocardiogram (TEE)
    Intervention Description
    Pre-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) until a PG ≥ 50mmHg is achieved (DBT peak dose). The DBT peak dose (DBT-pd) will be recorded. Post-CPB provocation test at the DBT-pd achieved preoperatively.
    Intervention Type
    Drug
    Intervention Name(s)
    Post-CPB Drug: Dobutamine Hydrochloride
    Other Intervention Name(s)
    Transthoracic or 2D Echocardiogram, Transesophageal Echocardiogram (TEE)
    Intervention Description
    Pre-CPB no intervention will be required. Post-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) or until postoperative provocable PG is >16 mmHg.
    Primary Outcome Measure Information:
    Title
    Analyze if TEE immediate post-myectomy LVOT gradients, may be reproduced with provocation dobutamine test in HOCM patients, when compared to TTE LVOT gradients performed within 6 months post-myectomy, to prove septal myectomy efficacy.
    Description
    The preoperative gradients obtained by TTE, with and without stress test, within 6 months pre-myectomy, will be compared with the intraoperative TEE pre-myectomy gradients at baseline (before and after DBT stress test). The post-myectomy TEE gradients (before and after DBT stress test), will be compared with the follow up TTE gradients with and without stress test, performed within 6 months post-myectomy, to assess short term outcomes.
    Time Frame
    Pre-operative up to 6 months, Immediate Intra-operative Pre-myectomy, Immediate Intra-operative Post-myectomy and Post-operative up to 6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: HOCM refractory to medical treatment with symptoms like syncope, angina or NYHA functional classes III and IV, with a resting gradient or provocable gradient equal or greater than 50 mmHg, requiring surgical intervention. Absence of other cardiac or systemic diseases capable of producing hypertrophy. Sinus rhythm. Exclusion Criteria: Patient refusal. Patient unable to give consent. TEE contraindication. Different rhythm than sinus. Other systemic diseases capable of producing hypertrophy. Severe Aortic or coronary artery pathology.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Azad Mashari, MD
    Phone
    (416) 340-4800
    Ext
    5164
    Email
    azad.mashari@uhn.ca
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jo Carroll
    Phone
    416 340-4800
    Ext
    3243
    Email
    jo.carroll@uhn.ca
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jacobo Moreno Garijo, MD
    Organizational Affiliation
    Sunnybrook Health Science Centre
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Azad Mashari, MD
    Organizational Affiliation
    University Health Network, Toronto
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Quantitative Assessment of Hypertrophic Obstructive Cardiomyopathy With Intraoperative Three-dimensional Transesophageal Echocardiography Under Provocative Dobutamine Stress Test

    We'll reach out to this number within 24 hrs